

Special Issue

Bioassay-Guided Isolation of Marine Natural Products for Drug Discovery

Message from the Guest Editor

From the potential human harm caused by the exquisitely potent dinoflagellate cytotoxins, maitotoxin and brevetoxin, through the knowledge gained regarding cellular function and metabolism from the use of latrunculin and laulimalide, right through to new blockbuster anticancer drugs like Eribulin mesylate and Trabectedin, the bioassay-guided isolation of new marine natural products has informed science and helped save many lives over the past half century. The new and exciting molecules sourced from the marine environment are varied in structure and, most importantly, the wide ranging and diverse potent bioactivities they possess. With a significantly greater number of phyla represented in our marine environments than that found on land, the sheer biodiversity found in the oceans, and hence opportunities for obtaining marine organisms, continue to make investigations of marine natural products a lucrative area for medicinal and biochemical research. As of this Special Issue, I cordially invite you to contribute your latest research describing bioassay-guided isolation and identification of novel, bioactive marine natural products, from any marine-based organisms.

Guest Editor

Dr. Rob Keyzers

School of Chemical and Physical Sciences, and Center for Biodiscovery, Victoria University of Wellington, Wellington 6140, New Zealand

Deadline for manuscript submissions

closed (31 August 2019)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed




mdpi.com/si/15793

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))